MedTrace Logo

Muscle Stem Cell Quality in Atrophy

NCT06077734 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 7

Last updated 2026-03-04

No results posted yet for this study

Summary

The goal of this clinical trial is to compare the quality of mesoangioblasts isolated from various patient groups suffering from muscle atrophy. This study includes cancer cachexia and muscle-impaired elderly and a control group of the same age.

The quality will be defined on these following outcomes:

* The number and distribution of the mesoangioblasts in a muscle biopsy to define if there are sufficient mesoangioblasts to start a culture.
* The proliferation capacity to define if we can culture them the numbers required for systemic treatment.
* The myogenic capacity to define if the mesoangioblasts are sufficiently capable to generate muscle fibres.

Participants will:

* Undergo a muscle biopsy (needle biopsy or rest material from surgery, \~50mg)
* Donate blood (\~20 ml)
* Fill in SARC-F questionnaire (evaluate sarcopenia score)
* Fill in SQUASH questionnaire (evaluate physical activity of previous week) Researchers will compare groups (muscle-impaired elderly vs control; cancer cachexia vs control) to see if there is a difference regarding quality. These results will define the potential of autologous mesoangioblast therapy within these groups.

Conditions

  • Muscle Weakness
  • Atrophy, Muscle
  • Cachexia
  • Sarcopenia
  • Stem Cell Transplantation
  • Mesenchymal Stem Cells

Interventions

OTHER

In vitro analyse

In vitro analysis on isolated mesoangioblasts obtained from muscle biopsies

Sponsors & Collaborators

  • Maastricht University Medical Center

    lead OTHER

Principal Investigators

  • Monique Hochstenbag, MD, PhD · Maastricht University Medical Centre

  • Bert Smeets, Professor · Maastricht University

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-27
Primary Completion
2026-02-02
Completion
2026-02-16

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06077734 on ClinicalTrials.gov